Athira Pharma Inc at Jefferies CNS & Neuro Summit Transcript
Hi, everyone. I'm Andrew Tsai, senior biotech analyst here at Jefferies. Thanks for joining us. And for this session, we have the Athira team. Mark Litton, to my right, CEO, President; and to his right, Andrew Gengos, CFO.
Welcome both of you.
Thank you for having us.
Questions & Answers
So maybe, we'll spend a brief couple of minutes talking about the Athira story. So for those in the audience who are less familiar, maybe talk about what you're working on, what your lead asset is, and what kind of milestones can we look forward to in the next couple of months?
Sure, sure. And thank you for having us. So Athira is a late-stage clinical biotech company. We're completely focused on neurodegeneration, and we're taking sort of a novel approach where we're using a natural repair mechanism
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
